Mobile Menu
CY3
Dragon Pharma

CY3

Product Information Compound Details
Dragon Pharma
Active Formula Clenbuterol / T3 / Yohimbine Stack
6.02 mg/tablet
Clenbuterol HCL 37 mcg
Liothyronine Sodium 25 mcg
Yohimbine HCL 5.4 mg
Total Strength 6.02 mg/tablet
Package 100 Tablets 602 mg total labeled content
Form Oral Tablet
Formula Triple-Action Thermogenic Stack
Drug Class Beta-2 Agonist / Thyroid Hormone / Alpha-2 Antagonist
Manufacturer Dragon Pharma
$39.00
Shipping :
International
U.S. Domestic
Buy 5+ for $36.27 and save $13.65
  • Overview
  • Profile
  • Usage
  • Safety
  • Shipping
  • Storage
  • FAQ
  • Reviews
Product Overview

CY3 by Dragon Pharma

CY3 is an oral thermogenic tablet manufactured by Dragon Pharma containing Clenbuterol HCL 37 mcg, Liothyronine Sodium 25 mcg, and Yohimbine HCL 5.4 mg per tablet.

CY3 Oral

CY3 is a combination oral tablet containing three active substances: clenbuterol hydrochloride, liothyronine sodium, and yohimbine hydrochloride. Clenbuterol is a beta-2 adrenergic agonist that stimulates lipolysis and thermogenesis in adipose tissue. Liothyronine sodium (T3) is a synthetic thyroid hormone that increases basal metabolic rate and energy expenditure. Yohimbine hydrochloride is an alpha-2 adrenergic receptor antagonist that promotes lipolysis, particularly in stubborn fat areas. This triple-action formula is not approved by the FDA for human use in the United States.

In non-medical bodybuilding and fitness contexts, CY3 is commonly referenced as a potent thermogenic stack for accelerating fat loss during cutting phases. Each component targets a different pathway: clenbuterol stimulates beta-2 receptors, liothyronine increases metabolic rate through thyroid hormone pathways, and yohimbine blocks alpha-2 receptors that inhibit fat mobilization. The combination is frequently referenced in bodybuilding communities as a "triple threat" for stubborn fat reduction.

The combination of these three compounds carries substantial cardiovascular and metabolic risks. Clenbuterol has been associated with serious cardiac adverse events including myocardial infarction and arrhythmias, particularly at the supratherapeutic doses used in non-medical contexts. Liothyronine at supraphysiologic doses can cause cardiac arrhythmias, bone mineral density loss, and adrenal crisis in susceptible individuals. Yohimbine can cause anxiety, elevated blood pressure, and serious cardiovascular events. Non-medical use of this combination falls outside approved indications and is strongly cautioned against.

Key Benefits of CY3

  • Triple-action thermogenic formula targeting multiple fat-loss pathways
  • Clenbuterol component stimulates beta-2 adrenergic lipolysis
  • Liothyronine component increases metabolic rate
  • Yohimbine component blocks alpha-2 adrenergic receptors
  • Convenient single-tablet oral administration
Product Profile

CY3 Profile

CY3 is a combination thermogenic tablet containing three distinct active substances, each targeting a different mechanism involved in lipolysis and metabolic rate regulation.

Triple-Action Thermogenic Combination

CY3 combines three compounds with complementary mechanisms. Clenbuterol hydrochloride is a beta-2 adrenergic agonist with a half-life of approximately 35 hours, providing prolonged stimulation of lipolysis in adipose tissue. Liothyronine sodium is a synthetic form of the thyroid hormone T3 with a half-life of approximately 2.5 days, increasing basal metabolic rate and thermogenesis. Yohimbine hydrochloride is an alpha-2 adrenergic antagonist with a half-life of approximately 0.5 hours, blocking the receptors that inhibit fat mobilization, particularly in stubborn fat areas.

The rationale for combining these compounds is to target multiple rate-limiting steps in fat metabolism simultaneously. Clenbuterol and yohimbine both stimulate lipolysis through adrenergic pathways, while liothyronine increases the overall metabolic rate at which liberated fatty acids are oxidized. This triple mechanism is not supported by clinical trials for this specific combination, and the safety of the combination has not been established.

Each component carries significant risks at supraphysiologic doses. Clenbuterol has been linked to cardiac ischemia, arrhythmias, and myocardial infarction in athletes. Liothyronine at doses exceeding physiologic replacement can precipitate arrhythmias, accelerate bone loss, and worsen glycemic control. Yohimbine has been associated with anxiety, hypertension, and rare but serious cardiovascular events.

Defining Characteristic

Multi-Pathway Thermogenic Stack

CY3 is distinguished by its triple-action formula combining beta-2 agonism, thyroid hormone supplementation, and alpha-2 antagonism. This multi-pathway approach is potent but carries compounded cardiovascular and metabolic risks.

CY3 vs Other Dragon Pharma Preparations

Dragon Pharma offers multiple compounds discussed in bodybuilding contexts. CY3's triple-action thermogenic mechanism contrasts with single-agent fat-loss compounds such as Clenbuterol (clenbuterol alone) or T3 (liothyronine alone). It is also distinct from GW501516, a PPARδ agonist with a different metabolic mechanism. The combination approach in CY3 is not supported by clinical trials, and the individual components carry independent risks that may compound when used together.

Dosage & Usage

CY3 Dosage & Usage

The information below is provided for educational reference only. CY3 is not approved by the FDA for human use in the United States. Non-medical use falls outside approved indications and carries significant health risks.

Typical Dosage Ranges

No safe or effective dosage has been established for CY3 as a combination product. In non-medical bodybuilding contexts, combination thermogenic products are referenced with significant variability. The individual components have established reference points: clenbuterol is commonly referenced at 80–120 mcg/day in non-medical contexts, liothyronine at 25–75 mcg/day in cutting protocols, and yohimbine at 0.2 mg/kg bodyweight (approximately 14–22 mg/day) for fat-loss purposes.

Use Case Common Reference Range (per component) Frequency
Clenbuterol (non-medical) 80–120 mcg / day Split doses, 2-week cycles
Liothyronine (non-medical) 25–75 mcg / day Split doses, 4–8 week cycles
Yohimbine (fat loss) 0.2 mg / kg / day Split into 2–4 doses

Stacking & Cycle Considerations

CY3 is itself a stacked combination product. In non-medical contexts, users sometimes further stack it with other compounds such as Clenbuterol or T3, which would duplicate the active components and dangerously increase exposure. Combining CY3 with additional stimulants or thyroid hormones is strongly cautioned against due to compounded cardiovascular risk.

Managing Side Effects

The combination of clenbuterol, liothyronine, and yohimbine creates compounded cardiovascular stress. Clenbuterol can cause tachycardia, palpitations, hypertension, and myocardial injury. Liothyronine at supraphysiologic doses can precipitate atrial fibrillation, angina, and bone density loss. Yohimbine can cause anxiety, increased blood pressure, and in rare cases serious cardiovascular events. The simultaneous use of multiple stimulatory agents significantly increases the risk of adverse cardiac events.

Important

Individual Response Varies

CY3 is not approved for human use and combines multiple active substances with significant independent risks. The information above is for educational reference and does not constitute medical advice. Non-medical use is strongly cautioned against.

Safety & Information

CY3 Safety Information

CY3 combines three active substances that individually carry significant health risks. The combination has not been evaluated for safety or efficacy in clinical trials.

Important Safety Information

CY3 is not approved by the FDA for human use. Clenbuterol is restricted to veterinary use in the United States. Liothyronine is FDA-approved for hypothyroidism and certain thyroid conditions but is not indicated for weight loss. Yohimbine is available as a prescription drug for erectile dysfunction but is not approved for fat loss. The combination of these three substances has not been studied, and their simultaneous use may compound cardiovascular and metabolic risks.

Important

Non-Medical Use

CY3 has no approved human indication as a combination product. Non-medical use falls outside approved indications and carries significant health risks including cardiac arrhythmias, myocardial injury, and endocrine disruption. Product strength and laboratory verification do not establish safety for human consumption.

Potential Adverse Effects

Cardiovascular effects: Clenbuterol has been associated with supraventricular tachycardia, atrial fibrillation, myocardial ischemia, myocardial infarction, and cardiomyopathy. A case report documented ST-elevation myocardial infarction in a young athlete using clenbuterol at 120–180 mcg daily. Liothyronine at supraphysiologic doses can cause increased heart rate, cardiac wall thickness, angina, and arrhythmias. Yohimbine can increase blood pressure and heart rate and has been linked to serious cardiovascular events in case reports. The combination of these cardiovascular effects is a major safety concern.

Metabolic and endocrine effects: Liothyronine over-replacement can cause hyperthyroidism symptoms, accelerate bone mineral density loss, and worsen glycemic control in diabetic patients.

Neurological and psychiatric effects: Yohimbine commonly causes anxiety and nervousness, and can cause increased blood pressure and gastrointestinal symptoms.

Drug interactions: Yohimbine potently inhibits CYP2D6 and interacts with multiple medications, potentially increasing the risk of adverse effects when combined with other drugs.

Conditions Requiring Medical Evaluation

Given the compounded cardiovascular risks, individuals with pre-existing heart conditions, hypertension, arrhythmias, or thyroid disorders are at heightened risk. Yohimbine should be avoided during pregnancy and lactation. Liothyronine is contraindicated in patients with uncorrected adrenal insufficiency. Any consideration of CY3 exposure warrants comprehensive medical evaluation including cardiac assessment, thyroid function, blood pressure, and electrolyte monitoring.

Monitoring During Therapy

There is no established monitoring protocol for non-medical CY3 use. For any human exposure, cardiac function, blood pressure, heart rate, thyroid function, and general health status should be assessed by a qualified healthcare professional. No safe monitoring parameters have been established for this combination because human safety data is absent.

Product Care

Storage & Handling

Store in a cool, dry place away from direct light and moisture. Keep the product in its original packaging and out of the reach of children. This product is not for human consumption.

Further Safety Information
DailyMed Liothyronine Sodium Label Mayo Clinic Yohimbine Information
Shipping & Authenticity

Shipping & Product Authenticity

CY3 is supplied through the Dragon Pharma distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.

USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply

Discreet Delivery & Original Packaging

The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the Dragon Pharma distribution chain.

What to Expect

  • Orders are processed after payment confirmation
  • USA Domestic shipping is typically faster when local stock is selected
  • International orders include tracking, though update frequency may vary by destination
  • Multiple warehouses may result in separate shipments when applicable

Authenticity Verification

To verify your CY3 product, cross-check the security features on the packaging against Dragon Pharma's official presentation. Original packaging helps reinforce product legitimacy.

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

CY3 Storage

Proper storage conditions help preserve tablet integrity and overall product stability throughout shelf life.

Recommended Conditions

Store in a cool, dry place away from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the tablets.

Keep the tablets in their original packaging until use. Do not use if the packaging appears compromised or if the tablets show signs of degradation.

Keep out of reach of children. This product is not for human consumption.

Quick Reference

Do & Don't

  • Do store in a cool, dry place
  • Do keep in original packaging
  • Do inspect tablets before use
  • Don't expose to direct sunlight
  • Don't store in humid environments
  • Don't use if tablets appear abnormal
Frequently Asked Questions

CY3 FAQ

Answers to common questions about CY3, its active substances, mechanisms, dosing, and safety.

What is CY3 used for?

CY3 is a combination thermogenic product containing clenbuterol, liothyronine, and yohimbine. It has no approved medical use as a combination product. In non-medical bodybuilding contexts, it is referenced for accelerated fat loss during cutting phases, though such use falls outside approved indications and carries significant health risks.

How often should CY3 be taken?

No established dosing protocol exists for CY3 as a combination product. The individual components have different half-lives and dosing considerations. Clenbuterol is typically dosed once or twice daily due to its 35-hour half-life. Liothyronine is typically dosed once daily. Yohimbine is often split into multiple daily doses.

What do the active substances in CY3 do?

Clenbuterol is a beta-2 adrenergic agonist that stimulates lipolysis. Liothyronine is a thyroid hormone that increases metabolic rate. Yohimbine is an alpha-2 adrenergic antagonist that promotes fat mobilization. Each targets a different pathway involved in fat metabolism.

Is CY3 approved for human use?

No. CY3 is not approved by the FDA for human use. Clenbuterol is restricted to veterinary use in the US. Liothyronine is approved for hypothyroidism but not for weight loss. Yohimbine is approved for erectile dysfunction but not for fat loss. The combination is not approved.

What are the risks of CY3?

The combination carries compounded cardiovascular risks. Clenbuterol has been associated with myocardial infarction, arrhythmias, and cardiomyopathy. Liothyronine at supraphysiologic doses can cause cardiac arrhythmias and bone loss. Yohimbine can cause anxiety, hypertension, and serious cardiovascular events. Combining multiple stimulatory agents significantly increases cardiac risk.

What is the difference between CY3 and Clenbuterol alone?

CY3 contains clenbuterol plus liothyronine and yohimbine. Clenbuterol alone (available as Clenbuterol) provides only beta-2 adrenergic stimulation. CY3 adds thyroid hormone and alpha-2 antagonism for a multi-pathway approach, but this also compounds the cardiovascular and metabolic risks.

What is the difference between CY3 and T3 alone?

CY3 contains liothyronine (T3) plus clenbuterol and yohimbine. T3 alone (available as T3) increases metabolic rate through thyroid pathways. CY3 adds adrenergic stimulation from clenbuterol and yohimbine, creating a more potent but riskier combination.

Is 6.02 mg of CY3 a lot?

CY3 has no approved human dose. The total tablet weight is 6.02 mg, comprising clenbuterol 37 mcg, liothyronine 25 mcg, and yohimbine 5.4 mg. The clenbuterol and liothyronine amounts are in microgram quantities, while yohimbine is in milligram quantities, reflecting their different potencies.

What strength is CY3?

CY3 is labeled at 6.02 mg total per tablet, comprising Clenbuterol HCL 37 mcg, Liothyronine Sodium 25 mcg, and Yohimbine HCL 5.4 mg. It is supplied in a 100-tablet package.

Does CY3 affect blood pressure?

Yes. Clenbuterol can cause hypertension and tachycardia. Yohimbine commonly increases blood pressure and heart rate. Liothyronine at supraphysiologic doses can also increase heart rate and cardiac contractility. The combination may have additive effects on blood pressure.

No reviews found

Please log in to write CY3 review.

Related Offers
Lab Tested
Domestic & International
-50% OFF
Winstrol 50 mg
Dragon Pharma, Europe
Winstrol 50 mg
Product Information Compound Details
Dragon Pharma
Active Substance Stanozolol 17-alpha-alkylated oral anabolic steroid
50 mg/tablet
Strength 50 mg/tablet
Package 100 Tablets 5,000 mg total labeled content
Form Oral Tablet
Half-Life Approximately 9 Hours
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
Latest Laboratory Result 48.62 mg April 18, 2025 · 97.24% of label claim View
$40.00 $80.00
You will save $40.00
Lab Tested
Domestic & International
Anavar 50 mg
Dragon Pharma, Europe
Anavar 50 mg
Product Information Compound Details
Dragon Pharma
Active Substance Oxandrolone 17-alpha-alkylated oral anabolic steroid
50 mg/tablet
Strength 50 mg/tablet
Package 100 Tablets 5,000 mg total labeled content
Form Oral Tablet
Half-Life Approximately 9 Hours
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
Latest Laboratory Result 48.26 mg January 13, 2026 · 96.52% of label claim View
$275.00
Lab Tested
Domestic & International
Buy 5+ for $46.50 and save $17.50
Nolvadex 20 mg
Dragon Pharma, Europe
Nolvadex 20 mg
Product Information Compound Details
Dragon Pharma
Active Substance Tamoxifen Citrate Selective estrogen receptor modulator (SERM)
20 mg/tablet
Strength 20 mg/tablet
Package 100 Tablets 2,000 mg total labeled content
Form Oral Tablet
Drug Class Selective Estrogen Receptor Modulator
Manufacturer Dragon Pharma
Half-Life Approximately 5–7 Days
Latest Laboratory Result 21.05 mg/tablet April 18, 2025 · 105.25% of label claim View
$50.00
Buy 5+ for $46.50 and save $17.50
Lab Tested
Domestic & International
Clenbuterol 40 mcg
Dragon Pharma, Europe
Clenbuterol 40 mcg
Product Information Compound Details
Dragon Pharma
Active Substance Clenbuterol Hydrochloride Beta-2 adrenergic agonist
40 mcg/tablet
Strength 40 mcg/tablet
Package 100 Tablets 4,000 mcg total labeled content
Form Oral Tablet
Half-Life Approximately 35 Hours
Drug Class Beta-2 Agonist
Manufacturer Dragon Pharma
Latest Laboratory Result 39.56 mcg August 31, 2024 · 98.90% of label claim View
$44.00

Add to Cart - Product(s)

Close Button
Empty

Total Cost:

50% OFF Weekly Deals 40% OFF All Peptides